---
title: "Craig-Hallum Remains a Buy on MaxCyte (MXCT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286155462.md"
description: "Craig-Hallum analyst Matt Hewitt has maintained a Buy rating on MaxCyte (MXCT), with shares closing at $0.82. The analyst consensus for MaxCyte is a Moderate Buy, with an average price target of $4.00. Hewitt, who covers the Healthcare sector, has an average return of -5.1% and a 36.96% success rate on his stock recommendations."
datetime: "2026-05-12T20:39:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286155462.md)
  - [en](https://longbridge.com/en/news/286155462.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286155462.md)
---

# Craig-Hallum Remains a Buy on MaxCyte (MXCT)

In a report released yesterday, Matt Hewitt from Craig-Hallum maintained a Buy rating on MaxCyte. The company’s shares closed today at $0.82.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Hewitt covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Ligand Pharma, and Maravai Lifesciences Holdings. According to TipRanks, Hewitt has an average return of \-5.1% and a 36.96% success rate on recommended stocks.

Currently, the analyst consensus on MaxCyte is a Moderate Buy with an average price target of $4.00.

### Related Stocks

- [MXCT.US](https://longbridge.com/en/quote/MXCT.US.md)
- [BLFS.US](https://longbridge.com/en/quote/BLFS.US.md)
- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [MRVI.US](https://longbridge.com/en/quote/MRVI.US.md)

## Related News & Research

- [River Global Investors Discloses Investment in MaxCyte with 6.1% Stake](https://longbridge.com/en/news/286427947.md)
- [Park Dental Partners, Inc. (PARK) Gets a Buy from Craig-Hallum](https://longbridge.com/en/news/286154642.md)
- [Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/286913304.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)